Researchers from Japan have uncovered direct evidence showing how ketamine exerts its rapid antidepressant effects in ...

Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

PET-CT is widely recommended in international clinical guidelines, including those of the European Association of Nuclear ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

Fortunately, a PET scan showed no evidence of cancer in Romano’s body. Still, her doctor recommended continuing with what she described as a “protocol,” which includes supplements, eight weeks of ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

And it costs all of us ...

A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little as four weeks, and potentially even at the start of treatment, according to new research ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...